AR106477A1 - PHARMACEUTICAL COMBINATION OF ANTAGONIST RECEIVER NK3 AND BIGUANIDAS - Google Patents

PHARMACEUTICAL COMBINATION OF ANTAGONIST RECEIVER NK3 AND BIGUANIDAS

Info

Publication number
AR106477A1
AR106477A1 ARP160103263A ARP160103263A AR106477A1 AR 106477 A1 AR106477 A1 AR 106477A1 AR P160103263 A ARP160103263 A AR P160103263A AR P160103263 A ARP160103263 A AR P160103263A AR 106477 A1 AR106477 A1 AR 106477A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically effective
biguanides
effective salts
antagonist
receptor antagonist
Prior art date
Application number
ARP160103263A
Other languages
Spanish (es)
Inventor
Kshirsagar Samadhan
Pandya Arti
Joharapurkar Amit
Banerjee Kaushik
Jain Mukul
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of AR106477A1 publication Critical patent/AR106477A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición sinérgica conformada por antagonista del receptor NK3 o sus sales farmacéuticamente efectivas, y biguanidas o sus sales farmacéuticamente efectivas, para el tratamiento de PCOS y trastornos relacionados. Combinación sinérgica que comprende combinaciones de un antagonista del receptor NK3 o sus sales farmacéuticamente efectivas, y biguanidas o sus sales farmacéuticamente efectivas en una composición farmacéutica en una sola unidad. Métodos para preparar dichas composiciones farmacéuticas por separado en forma de kit que contiene ambos agentes activos, y con métodos para tratar un sujeto con dicha composición. Reivindicación 2: La composición sinérgica de acuerdo con la reivindicación 1, caracterizada porque el antagonista del receptor NK3 se selecciona entre Talnetant (SB223412), AZD-4901 y AZD-2624. Reivindicación 3: La composición sinérgica de acuerdo con la reivindicación 1, caracterizada porque las biguanidas son Metformina.A synergistic composition consisting of NK3 receptor antagonist or its pharmaceutically effective salts, and biguanides or its pharmaceutically effective salts, for the treatment of PCOS and related disorders. Synergistic combination comprising combinations of an NK3 receptor antagonist or its pharmaceutically effective salts, and biguanides or its pharmaceutically effective salts in a pharmaceutical composition in a single unit. Methods for preparing said pharmaceutical compositions separately in kit form containing both active agents, and with methods for treating a subject with said composition. Claim 2: The synergistic composition according to claim 1, characterized in that the NK3 receptor antagonist is selected from Talnetant (SB223412), AZD-4901 and AZD-2624. Claim 3: The synergistic composition according to claim 1, characterized in that the biguanides are Metformin.

ARP160103263A 2015-10-29 2016-10-26 PHARMACEUTICAL COMBINATION OF ANTAGONIST RECEIVER NK3 AND BIGUANIDAS AR106477A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN4102MU2015 2015-10-29

Publications (1)

Publication Number Publication Date
AR106477A1 true AR106477A1 (en) 2018-01-17

Family

ID=57321359

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103263A AR106477A1 (en) 2015-10-29 2016-10-26 PHARMACEUTICAL COMBINATION OF ANTAGONIST RECEIVER NK3 AND BIGUANIDAS

Country Status (3)

Country Link
AR (1) AR106477A1 (en)
TW (1) TW201729808A (en)
WO (1) WO2017072629A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110840869A (en) * 2019-10-15 2020-02-28 四川大学华西第二医院 Application of metformin in preparation of medicines for treating endometriosis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226535B1 (en) 1994-05-27 2009-03-30 Glaxosmithkline Spa Quinoline derivatives as tachykinin nk3 receptor antagonists, pharmaceutical compositions containing them, and their use
AR004735A1 (en) 1995-11-24 1999-03-10 Smithkline Beecham Spa CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
CN1207730A (en) 1995-11-24 1999-02-10 史密丝克莱恩比彻姆股份公司 Quinoline derivs.
GB9524137D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
CN1406225A (en) 1998-11-20 2003-03-26 葛兰素史密丝克莱恩有限公司 Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
ES2237408T3 (en) * 1999-01-25 2005-08-01 Smithkline Beecham Corporation ANTIANDROGENS AND PROCEDURES TO TREAT AN ILLNESS.
JP2002540206A (en) * 1999-03-11 2002-11-26 ニューロゲン コーポレイション Aryl-fused 2,4-disubstituted pyridines: NK3 receptor ligands
GB0027701D0 (en) 2000-11-13 2000-12-27 Smithkline Beecham Spa Novel compounds
JP2008546767A (en) 2005-06-23 2008-12-25 アストラゼネカ・アクチエボラーグ Quinoline 3-sulfonate as modulator of NK3 receptor
BRPI0815658A2 (en) 2007-08-07 2015-02-18 Hoffmann La Roche Pyrolidine Aryl Ether as NK3 RECEPTOR ANTAGONISTS
CN102282139B (en) 2009-01-30 2014-06-18 弗·哈夫曼-拉罗切有限公司 Piperidine derivatives as NK3 receptor antagonists
US8318759B2 (en) 2009-02-18 2012-11-27 Hoffmann-La Roche Inc. Pyrrolidine derivatives as NK3 receptor antagonists
AU2014255512A1 (en) * 2013-04-19 2015-11-12 Astrazeneca Ab A NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)

Also Published As

Publication number Publication date
TW201729808A (en) 2017-09-01
WO2017072629A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
CO2017004525A2 (en) Ror-gamma inhibitory dihydropyrrolopyridines
SV2017005461A (en) BENZAMIDS REPLACED WITH 1,3-TIAZOL-2-ILO
CL2020000215A1 (en) Compounds and compositions for treating conditions associated with nlrp activity.
CL2018003429A1 (en) Novel compounds such as autotaxin inhibitors and pharmaceutical compositions that comprise them.
DOP2016000208A (en) BENZIMIDAZOL-2-AMINAS AS MIDH1 INHIBITORS
UY37098A (en) ROR-GAMMA MODULATORS
DOP2017000097A (en) COMPOSITIONS AND METHODS OF USE TO TREAT METABOLIC DISORDERS
GT201600233A (en) COMPOUNDS AND COMPOSITIONS AS AGENTS OF THE TOLL TYPE 7 RECEIVER
DOP2020000102A (en) HELPFUL COMPOUNDS TO INHIBIT CDK7
CL2016002812A1 (en) Use of 3-2,3,5,6-tetrafluoro-3-trifluoromethoxy-biphenyl-4-ylcarbamoyl-thiophene-2-carboxylic acid to prepare a medicament useful for treating an eye disease that is uveitis, dry eye or caused by a adenovirus composition formulation.
BR112017008659A2 (en) ? gip agonist methods and compounds?
CL2016002169A1 (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders.
UY36224A (en) TRICYCLIC COMPOUNDS OF IMIDAZO-PIRIMIDINONA
CL2017001301A1 (en) Stabilized ophthalmic compositions of omega 3
ZA201906100B (en) Combination of a ppar agonist with a fxr agonist
CL2017000845A1 (en) Lysine Gingipain Inhibitors
AR112144A1 (en) COMPOUNDS FOR THE TREATMENT OF SARCOMA
CO2017002312A2 (en) Substituted bicyclic compounds
CR20150653A (en) NEW COMPOUNDS FOR CANCER TREATMENT
EA201892475A1 (en) OXABOROLIC COMPLEX ETHERS, THEIR APPLICATION
CO2018012180A2 (en) Treatment methods for cholestatic and fibrotic diseases
UY36732A (en) PIRIDIN PIRAZINONAS NOVEDOSAS AS BROMODOMINIUM INHIBITORS OF THE BET FAMILY
AR106477A1 (en) PHARMACEUTICAL COMBINATION OF ANTAGONIST RECEIVER NK3 AND BIGUANIDAS
CL2015002188A1 (en) Topical eye analgesic agents
MX2020003554A (en) MODULATORS OF ENaC EXPRESSION.

Legal Events

Date Code Title Description
FB Suspension of granting procedure